Purpose Lapatinib plus trastuzumab improves outcomes relative to lapatinib alone in heavily
pretreated, human epidermal growth factor receptor 2–positive metastatic breast cancer …

Purpose Phase III EGF104900 data demonstrated that lapatinib plus trastuzumab
significantly improved progression-free survival (PFS) and clinical benefit rate versus …

Purpose The efficacy of lapatinib versus trastuzumab combined with taxanes in the first-line
setting of human epidermal growth factor receptor 2 (HER2)–positive metastatic breast …

Purpose Lapatinib (L) is approved in combination with capecitabine or letrozole for patients
with trastuzumab-resistant HER2-positive metastatic breast cancer (MBC). However, there is …

Background This phase IB, open-label, dose-escalation study evaluated the safety,
tolerability, and optimally tolerated regimen (OTR) of lapatinib in combination with docetaxel …

Purpose Preclinical studies in ErbB2-positive cell lines demonstrated a synergistic
interaction between lapatinib and trastuzumab, suggesting that dual blockade is more …

Background Preclinical data suggest that treatment with lapatinib reinduces sensitivity to
trastuzumab in human epidermal growth factor receptor 2 (HER2)-positive breast cancer …

The aim of the present study was to determine the efficacy and safety of lapatinib‑based
treatment for patients with human epidermal growth factor receptor‑2‑positive (HER2+) …

Background. Recent data support the hypothesis that combining lapatinib and trastuzumab
with taxane chemotherapy may offer added clinical benefit to patients with human epidermal …

Background The mechanisms of resistance to anti-human epidermal growth factor receptor
2 (HER 2) therapies are unclear but may include the tyrosine-protein kinase Met (c-Met) …